These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7090422)

  • 61. Reversed-phase liquid chromatography of adriamycin and daunorubicin and their hydroxyl metabolites adriamycinol and daunorubicinol.
    Eksborg S
    J Chromatogr; 1978 Feb; 149():225-32. PubMed ID: 649731
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
    Bains OS; Grigliatti TA; Reid RE; Riggs KW
    J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
    [TBL] [Abstract][Full Text] [Related]  

  • 63. DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.
    Schneider YJ; Baurain R; Zenebergh A; Trouet A
    Cancer Chemother Pharmacol; 1979; 2(1):7-10. PubMed ID: 498422
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Studies on the comparative distribution and biliary excretion of doxorubicin and 4'-epi-doxorubicin in mice and rats.
    Broggini M; Colombo T; Martini A; Donelli MG
    Cancer Treat Rep; 1980; 64(8-9):897-904. PubMed ID: 6934850
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The pharmacokinetics of polymer-bound adriamycin.
    Seymour LW; Ulbrich K; Strohalm J; Kopecek J; Duncan R
    Biochem Pharmacol; 1990 Mar; 39(6):1125-31. PubMed ID: 2322298
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Flow cytometric monitoring of cellular anthracycline accumulation in murine leukemic cells.
    Krishan A; Sauerteig A; Gordon K; Swinkin C
    Cancer Res; 1986 Apr; 46(4 Pt 1):1768-73. PubMed ID: 3948163
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.
    Sweatman TW; Israel M
    Cancer Chemother Pharmacol; 1987; 19(3):201-6. PubMed ID: 3472675
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacokinetic analysis of the metabolism of cocaine to norcocaine and N-hydroxynorcocaine in mice.
    Boyer CS; Petersen DR
    Drug Metab Dispos; 1992; 20(6):863-8. PubMed ID: 1362939
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Exploring multidrug resistance using rhodamine 123.
    Kessel D
    Cancer Commun; 1989; 1(3):145-9. PubMed ID: 2639727
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cellular pharmocodynamics of several anthrocycline antibiotics.
    Bachur NR; Steele M; Meriwether WD; Hildebrand RC
    J Med Chem; 1976 May; 19(5):651-4. PubMed ID: 1271407
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cellular pharmacology of amino acid derivatives of daunorubicin and doxorubicin in suspension of renal proximal tubules.
    Hjelle JT; Baurain R; Masquelier M; Trouet A
    J Pharmacol Exp Ther; 1984 May; 229(2):372-80. PubMed ID: 6585548
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
    Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
    Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Metabolic disposition of 5-iminodaunorubicin in the rat.
    Peters JH; Gordon GR; Kashiwase D; Acton EM
    Cancer Res; 1984 Apr; 44(4):1453-9. PubMed ID: 6704961
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Murine metabolism and disposition of iron:adriamycin complexes.
    Egorin MJ; Clawson RE; Ross LA; Friedman RD; Reich SD; Pollak A; Bachur NR
    Cancer Res; 1983 Jul; 43(7):3253-62. PubMed ID: 6189594
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of CYP2E1 and saturation kinetics in the bioactivation of thioacetamide: Effects of diet restriction and phenobarbital.
    Chilakapati J; Korrapati MC; Shankar K; Hill RA; Warbritton A; Latendresse JR; Mehendale HM
    Toxicol Appl Pharmacol; 2007 Feb; 219(1):72-84. PubMed ID: 17234228
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Extrahepatic tissue distribution, covalent binding, and toxicity of halothane in control and phenobarbital-pretreated rats.
    Rao GS; Grumley JO
    Pharmacol Ther Dent; 1978; 3(2-4):101-9. PubMed ID: 286368
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Role of cell pharmacokinetics in the modulation of modalities in the administration of anthracyclines].
    Tapiéro H; Boule D; Trincal G; Fourcade A
    Pathol Biol (Paris); 1987 Jan; 35(1):20-6. PubMed ID: 3550608
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dose-dependent kinetics and metabolism of 1,2-dichlorobenzene in rat: effect of pretreatment with phenobarbital.
    Hissink AM; Van Ommen B; Van Bladeren PJ
    Xenobiotica; 1996 Jan; 26(1):89-105. PubMed ID: 8851824
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Copper status and adriamycin treatment: effects on antioxidant status in mice.
    Zidenberg-Cherr S; Dreith D; Keen CL
    Toxicol Lett; 1989 Aug; 48(2):201-12. PubMed ID: 2772926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.